Show simple item record

dc.contributor.authorLesniewski-Kmak, K
dc.contributor.authorMoiseenko, V
dc.contributor.authorSaunders, Mark P
dc.contributor.authorWasan, H
dc.contributor.authorArgiles, G
dc.contributor.authorBorg, C
dc.contributor.authorCreemers, G
dc.contributor.authorFedyanin, M
dc.contributor.authorGlynne-Jones, R
dc.contributor.authorPfeiffer, P
dc.contributor.authorPunt, C
dc.contributor.authorStroyakovskiy, D
dc.contributor.authorTen Tije, A
dc.contributor.authorVan de Wouw, A
dc.contributor.authorKanehisa, A
dc.contributor.authorFougeray, R
dc.contributor.authorBusto, N
dc.contributor.authorAmellal, N
dc.contributor.authorVan Cutsem, E
dc.date.accessioned2018-10-15T16:52:45Z
dc.date.available2018-10-15T16:52:45Z
dc.date.issued2018-06
dc.identifier.citationPhase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis. 2018, 29(Suppl_5): Ann Oncolen
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.doi10.1093/annonc/mdy149.021
dc.identifier.urihttp://hdl.handle.net/10541/621272
dc.language.isoenen
dc.relation.urlhttps://academic.oup.com/annonc/article/doi/10.1093/annonc/mdy149.021/5039386en
dc.rightsArchived with thanks to Annals of Oncologyen
dc.titlePhase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentSzpitale Wojewodzkie w Gdyni/Gdansk Medical University, Gdynia, Polanden
dc.identifier.journalAnnals of Oncologyen
dc.contributor.institutionSzpitale Wojewodzkie w Gdyni/Gdansk Medical University, Gdynia, Poland
dc.contributor.institutionSaint-Petersburg Scientific Practical Center for Specialized Medical Care (oncological), St.Petersburg, Russian Federation
dc.contributor.institutionChristie Hospital NHS Foundation Trust, Manchester, UK
dc.contributor.institutionHammersmith Hospital, Department of Cancer Medicine, London, UK
dc.contributor.institutionDepartment of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain
dc.contributor.institutionUniversity Hospital Besançon, Besançon, France
dc.contributor.institutionCatharina Hospital, Eindhoven, Netherlands
dc.contributor.institutionN.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
dc.contributor.institutionMount Vernon Centre for Cancer Treatment, London, UK
dc.contributor.institutionDepartment of Oncology, Odense University Hospital, Odense, Denmark
dc.contributor.institutionAcademic Medical Center, University of Amsterdam, Amsterdam, Netherlands
dc.contributor.institutionMoscow City Oncology Hospital N62, Moscow, Russian Federation
dc.contributor.institutionAmphia Hospital Breda, Breda, Netherlands
dc.contributor.institutionVieCuri Medisch Centrum Noord-Limburg, Venlo, Netherlands
dc.contributor.institutionInstitut de Recherches Internationales Servier, Suresnes, France
dc.contributor.institutionInstitut de Recherches Internationales Servier, Suresnes, France
dc.contributor.institutionInstitut de Recherches Internationales Servier, Suresnes, France
dc.contributor.institutionServier Oncology, Suresnes, France
dc.contributor.institutionUniversity Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium


This item appears in the following Collection(s)

Show simple item record